Survival benefit of chemoradiotherapy in limited-stage mantle cell lymphoma: a National Cancer Database analysis. (PubMed, Blood Neoplasia) - Sep 26, 2026 - "Initial treatment was categorized to chemotherapy alone, radiotherapy (RT) alone, or combined chemotherapy plus RT (Chemo+RT), and outcomes were further stratified by stage and era of diagnosis (2004-2009 vs 2010-2015) to account for advances in systemic therapy, such as the adoption of bendamustine-rituximab for frontline therapy and the availability of Bruton tyrosine kinase inhibitors for relapsed disease. In this, to our knowledge, largest real-world analysis of limited-stage MCL to date, combined chemoimmunotherapy and RT was associated with a clinically meaningful survival benefit, including in the modern treatment era. These findings suggest that combined-modality therapy may be preferred for appropriately selected patients with limited-stage MCL."
Journal • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology
|
|
Allison C Rosenthal; Domitilla Baccon; Grzegorz S Nowakowski; Ivana N Micallef; Jacqueline F Wang; Javier L Munoz; Jihao Zhou; Jithma P Abeykoon; Jonas Paludo; Julio C Chavez; Madiha Iqbal; Muhamad Alhaj Moustafa; Robin R Klebig; Scott C Lester; Stephen M Ansell; Steven R Hwang; Suheil Albert Atallah-Yunes; Thomas E Witzig; Thomas M Habermann; William G Breen; Yucai Wang
|